 The purpose of this study is to investigate the safety and tolerability of AG013 in subjects who are at risk for oral mucositis OM and to assess clinical efficacy of AG013 in the reduction of signs and symptoms of OM in patients receiving induction chemotherapy for the treatment of their head and neck cancer. 